{"id":587709,"date":"2026-08-11T00:00:00","date_gmt":"2026-08-11T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unnecv0010-2026-biopharma-hypertension-unmet-need-unmet-need-resistant-hypertension-us-eu\/"},"modified":"2026-08-28T11:21:12","modified_gmt":"2026-08-28T11:21:12","slug":"unnecv0010-2026-biopharma-hypertension-unmet-need-unmet-need-resistant-hypertension-us-eu","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/unnecv0010-2026-biopharma-hypertension-unmet-need-unmet-need-resistant-hypertension-us-eu\/","title":{"rendered":"Hypertension &#8211; Unmet Need &#8211; Unmet Need &#8211; Resistant Hypertension (US\/EU)"},"content":{"rendered":"<p>Resistant hypertension (<abbr title=\"resistant hypertension\">RHTN<\/abbr>) has become a critical focus within the cardiovascular market because a substantial proportion of patients remain uncontrolled despite multidrug therapy, with longestablished regimens centered on <abbr title=\"renin-angiotensin-aldosterone system\">RAAS<\/abbr> inhibitors (<abbr title=\"angiotensin-converting enzyme\">ACE<\/abbr> inhibitors or <abbr title=\"angiotensin II receptor blocker\">ARB<\/abbr>s), <abbr title=\"calcium channel blocker\">CCB<\/abbr>s, thiazide-like diuretics, and the addition of spironolactone as the standard fourthline agent continuing to dominate care due to decades of clinician familiarity. Although these therapies are widely used, important gaps remain, fueling interest in emerging treatments from companies developing new mechanisms of action. The recent approval of Idorsia\u2019s aprocitentan (Tryvio \/ Jeragyo), the first new antihypertensive class in nearly 40 years, signals a meaningful change in this genericized landscape and highlights the importance of understanding how prescriber expectations are shifting. In this report, we explore which attributes cardiologists value most in current and future <abbr title=\"resistant hypertension\">RHTN<\/abbr> treatments, and through the <abbr title=\"Target Product Profile\">TPP<\/abbr> Simulator, we assess how physicians prioritize efficacy, safety, and other key product features in terms of efficacy and safety.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>How do cardiologists distinguish between established <abbr title=\"resistant hypertension\">RHTN<\/abbr> treatments and newer alternatives such as aprocitentan when assessing clinical and nonclinical factors?<\/li>\n<li>Which drug attributes most influence a cardiologist\u2019s prescribing decisions in <abbr title=\"resistant hypertension\">RHTN<\/abbr>?<\/li>\n<li>What trade-offs across different clinical attributes and price are acceptable to U.S. and European cardiologists for an emerging therapy?<\/li>\n<li>What are the prevailing areas of unmet need in treating <abbr title=\"resistant hypertension\">RHTN<\/abbr>?<\/li>\n<\/ul>\n<p><strong>Markets covered:<\/strong> United States, France, Germany, United Kingdom<\/p>\n<p><strong>Primary research: <\/strong>Survey of 61 U.S. and 30 European endocrinologists fielded in June 2026<\/p>\n<p><strong>Key companies: <\/strong>Idorsia Pharmaceuticals, Pfizer, Viatris, Validus Pharmaceuticals, Waylis Therapeutics, Cheplapharm, Recordati Pharmaceuticals.<\/p>\n<p><strong>Key drugs: <\/strong>Tryvio, spironolactone, carvedilol, metoprolol, clonidine, doxazosin<\/p>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p><a>Unmet Need offers insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities, enabling you to:<\/a><\/p>\n<ul>\n<li>Evaluate clinical and nonclinical product attributes that influence treatment decisions through physicians\u2019 weightings and analysis of stated vs. derived importance.<\/li>\n<li>Pinpoint areas of high unmet need by assessing current drug performance against key attributes and treatment drivers.<\/li>\n<li>Analyze market scenarios for different target product profiles using the <abbr title=\"Target Product Profile\">TPP<\/abbr> Simulator.<\/li>\n<\/ul>\n","protected":false},"template":"","class_list":["post-587709","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-cardiovascular","biopharma-therapy-areas-hypertension","biopharma-product-unmet-need","biopharma-geography-us","biopharma-date-2609"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/587709","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=587709"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}